Cite
Schnadig ID, Agajanian R, Dakhil C, et al. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Manag Res. 2017;9:179-187doi: 10.2147/CMAR.S129059.
Schnadig, I. D., Agajanian, R., Dakhil, C., Gabrail, N., Vacirca, J., Taylor, C., Wilks, S., Braun, E., Mosier, M. C., Geller, R. B., Schwartzberg, L., & Vogelzang, N. (2017). APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer management and research, 9179-187. https://doi.org/10.2147/CMAR.S129059
Schnadig, Ian D, et al. "APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial." Cancer management and research vol. 9 (2017): 179-187. doi: https://doi.org/10.2147/CMAR.S129059
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Manag Res. 2017 May 19;9:179-187. doi: 10.2147/CMAR.S129059. eCollection 2017. PMID: 28579832; PMCID: PMC5446958.
Copy
Download .nbib